Patents by Inventor Matthew John Meyer

Matthew John Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220008426
    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.
    Type: Application
    Filed: March 3, 2021
    Publication date: January 13, 2022
    Inventors: Giordano CAPONIGRO, Vesselina COOKE, Matthew John MEYER, Darrin STUART
  • Publication number: 20210121460
    Abstract: The present invention relates to a pharmaceutical combination comprising dabrafenib, trametinib and an Erk-inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which MAPK pathway inhibition is beneficial, for example, in the treatment of cancers.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Inventors: Matthew John Meyer, Youzhen Wang
  • Patent number: 10973829
    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Giordano Caponigro, Vesselina Cooke, Matthew John Meyer, Darrin Stuart
  • Publication number: 20210040205
    Abstract: The present disclosure relates to anti-CD32b antibody molecules which selectively bind human CD32b. Also provided herein are compositions comprising anti-CD32b antibody molecules in combination with other compounds, and methods of using the combinations to treat subject with cancer.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 11, 2021
    Inventors: Sunyoung JANG, Haihui LU, Matthew John MEYER, Ryan MOLONY, Karrie WONG
  • Publication number: 20200405875
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: June 4, 2020
    Publication date: December 31, 2020
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William Mallet, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Patent number: 10786578
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Dylan Daniel, Catrin Finner, Bernhard Hubert Geierstanger, Thomas Huber, William Mallet, Matthew John Meyer, Weijia Ou, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Publication number: 20190358236
    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.
    Type: Application
    Filed: September 18, 2017
    Publication date: November 28, 2019
    Inventors: Giordano CAPONIGRO, Vesselina COOLE, Matthew John MEYER, Darrin STUART
  • Publication number: 20190345250
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: December 19, 2018
    Publication date: November 14, 2019
    Applicant: NOVARTIS AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Matthew John Meyer, Konstanin Petropoulos, Engin Toksoz
  • Patent number: 10238748
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: March 26, 2019
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Publication number: 20180193475
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 27, 2015
    Publication date: July 12, 2018
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Dylan DANIEL, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Thomas HUBER, William MALLET, Matthew John MEYER, Weijia OU, Siew Ho SCHLEYER, Kathrin Ulrike TISSOT-DAGUETTE
  • Patent number: 9982045
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: May 29, 2018
    Assignee: Novartis AG
    Inventors: Carl Uli Bialucha, Scott Collins, Clemens Dürr, Tiancen Hu, Mary Jo Janatpour, Matthew John Meyer
  • Publication number: 20170198040
    Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which selectively bind human CD32b. Also provided herein are compositions comprising the antibodies or antigen-binding fragments thereof, methods of using the antibodies or antigen-binding fragments thereof, and methods of making the antibodies or antigen-binding fragments thereof.
    Type: Application
    Filed: December 16, 2016
    Publication date: July 13, 2017
    Applicant: Novartis AG
    Inventors: Nicole BALKE, Thomas CALZASCIA, Stefan EWERT, Alan HARRIS, Heather Adkins HUET, Isabelle ISNARDI, Haihui LU, Matthew John MEYER, Nicholas WILSON, Fangmin WU
  • Publication number: 20170106095
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Publication number: 20170008964
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: July 7, 2016
    Publication date: January 12, 2017
    Applicant: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen HU, David Jenkins, Matthew John Meyer, Konstantin Petropoulos, Engin Toksoz
  • Patent number: 9498532
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 22, 2016
    Assignee: Novartis AG
    Inventors: David Bryant Batt, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Publication number: 20160046711
    Abstract: The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Carl Uli BIALUCHA, Scott COLLINS, Clemens DÜRR, Tiancen HU, Mary Jo JANATPOUR, Matthew John MEYER
  • Publication number: 20140308201
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • Publication number: 20140301946
    Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 9, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer